

Express Mail No. EV913329571US

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of:

Michael A. Zeligs

Confirmation No.:

9606

Serial No.:

10/616,477

Art Unit:

1618

Attorney Docket No.: 9439-015-999

Filed:

July 9, 2003

Examiner:

Nabila G. Ebrahim

For:

PHYTOCHEMICALS FOR THE

TREATMENT OF MASTALGIA, **ENDOMETRIOSIS AND HPV-**

RELATED CONDITIONS INCLUDING CERVICAL

DYSPLASIA

TERMINAL DISCLAIMER

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

The fee for processing the attached Terminal Disclaimer is believed to be \$65.00. Please charge the required fee to Jones Day Deposit Account No. 50-3013. A copy of this sheet is attached for accounting purposes.

Date:

September 26, 2007

Respectfully submitted

Thomas E. Friebel

(Reg. No.) 29,258

JONES DAY 222 East 41st Street

New York, New York 10017

(212) 326-3939


10/01/2007 CNEGA1

00000071 503013

10616477

02 FC:2814

65.00 DA





IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of:

Michael A. Zeligs

Confirmation No.:

9606

Serial No.:

10/616,477

Art Unit:

1618

Attorney Docket No.: 9439-015-999

Filed:

July 9, 2003

Examiner:

Nabila G. Ebrahim

For:

PHYTOCHEMICALS FOR THE TREATMENT OF MASTALGIA, ENDOMETRIOSIS AND HPV-RELATED CONDITIONS

INCLUDING CERVICAL

DYSPLASIA

TERMINAL DISCLAIMER

Mail Stop: AF Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

Your Petitioner, Michael A. Zeligs represents that he holds the position of Chief Executive Officer of BIORESPONSE L.L.C., the assignee of the entire 100% right, title and interest in and to application Serial No. 10/616,477 filed July 9, 2003, by virtue of an assignment from the inventor of Application Serial No. 10/616,477, recorded on December 2, 2003 at reel 014750 frame 0333.

BIORESPONSE L.L.C. is also the assignee of the entire 100% right, title and interest in and to application Serial No. 10/117,288 filed April 5, 2002 entitled "DIINDOLYLMETHANE FOR THE TREATMENT OF HPV INFECTION," by virtue of an assignment from the inventor of the Application Serial No. 10/117,288, recorded on September 5, 2002 at reel 013271 frame 0134.

Petitioner hereby disclaims the terminal part of any patent granted on the application Serial No. 10/616,477 which would extend beyond the expiration date of any patent granted on application Serial No. 10/117,288.

Petitioner hereby agrees that any patent so granted on application Serial No. 10/616,477 shall be enforceable only for and during such period that the legal title thereto shall be the same as the legal title to any patent granted on application Serial No. 10/117,288. Petitioner further agrees that this agreement is to run with any patent granted on application Serial No. 10/616,477 and is to be binding upon the grantee, its successors, and assigns.

Petitioner does not disclaim any terminal part of any patent granted on application Serial No. 10/616,477 prior to the expiration date of the full statutory term of any patent granted on application Serial No. 10/117,288 in the event that any patent grant on application Serial No. 10/117,288 later expires for failure to pay a maintenance fee, is held unenforceable, is found invalid, is statutorily disclaimed in whole or terminally disclaimed under 37 C.F.R. 1.321(a), has all claims canceled by a

reexamination certificate, or is otherwise terminated prior to the expiration of its full statutory term, except for the separation of legal title stated above.

Petitioner hereby confirms that he has reviewed the assignment and, to the best of his knowledge and belief, title is in the assignee seeking to take action in this matter and that he is empowered to act on behalf of BIORESPONSE L.L.C.

Petitioner hereby declares that all statements made herein of his own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issuing thereon.

Signed this 25 day of 22pt 2007.

BIORESPONSE L.L.C.

Name: Michael A. Zeligs
Position: Chief Executive Officer